Stock Analiz

Lisata Therapeutics, Inc. LSTA

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.21Market cap $13M
Open the interactive analysis →

Lisata Therapeutics, Inc. (LSTA) is a healthcare company listed in the US with a market value of about $13M. In the twelve months to September 30, 2026 it had revenue of $100000 and net income of -$17M, a net margin of -17159.0%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -70%.

About Lisata Therapeutics

Lisata Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $18M in 2014 to $170000 in 2025, a decline of about 34.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 68% over three years (dilution for shareholders). It spends 4676% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S130.7
P/B1.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-165.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-83.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-5877.5%
ROIC (5-yr avg.)-69.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$100000$170000$1M$0$0—————$35M
Net income-$17M-$17M-$20M-$21M-$54M-$27M-$8M-$19M-$16M$23M-$33M
Free cash flow-$22M-$16M-$19M-$20M-$21M-$22M-$9M-$19M-$20M-$21M-$25M
EPS (diluted)$-1.88$-1.91$-2.40$-2.58$-10.47$-7.45$-7.95$-28.20$-25.05$38.40$-74.84
Net margin-17159.0%-9756.5%-1998.5%———————-92.5%
ROIC—-115.9%-72.5%-47.7%-82.1%-29.6%-45.7%-92.2%-45.0%-31.8%-280.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Lisata Therapeutics pay a dividend?

Not currently.

Is Lisata Therapeutics a good stock to buy?

We do not give buy or sell advice. Lisata Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.